In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

Ventyx Biosciences has shared promising top-line results from a phase 2a study of its investigational central nervous system ...

Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.

The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators ...

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...